is a member of IndiaMART

Following details of the company have been verified

    Mabura Adalimumab Injection

    BrandMabura
    Packaging TypeVial
    ManufacturerHetero Healthcare
    Prescription/Non-PrescriptionPrescription
    CompositionAdalimumab
    FormInjection
    View in Hindi माबुरा अडालिमुमैब इंजेक्शन

    Specification :-

    ·         Brand Name : Mabura 

    ·         Content : Adalimumab

    ·         Packing : Pack Of 1 Vial

    ·         Strength : 40 mg

    ·         Form : Injection

    ·         Manufacture by: Hetero

    Note : Mabura Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug.....

    Exports To: Bangladesh | Germany | United States Of America | Canada | Bahrain

    Find products similar to Mabura Adalimumab Injection

    Find related categories

    Shipping Information

    AvailabilityIn Stock
    Ships fromNew Delhi
    ShippingAs per delivery location

    Product Image

    Mabura Adalimumab Injection image 1Mabura Adalimumab Injection image 2

    About the Company

    GST Registration Year
    2017
    Legal Status of Firm
    Proprietorship
    Nature of Business
    Trader - Retailer
    Number of Employees
    11 To 25 People
    Annual Turnover
    1.5 - 5 Cr
    IndiaMART Member Since
    Jan 2011
    GST
    07**********1Z2
    Import Export Code (IEC)
    *******185
    Exports to
    Bangladesh | Germany | United States Of America | Canada | Bahrain

    RadhaKishan Pharmaceuticals was established in 2011 is a exporter, supplier, retailer, wholesaler and trader of superior array of Anti Cancer Medicines. Our broad catalog of medicines comprises of Anti Cancer Tablets, Anti Cancer Capsules and Geftinat Tablets. We provide free home delivery of medicines as per the storage requirement to the patients in Delhi/NCR and India. We help patients by providing them the original and authentic AIDS & Cancer drugs at most economic and concussive rates.